Aragen Life Sciences, one of India’s leading contract research, development and manufacturing organisations (CRDMOs), commenced operations at Aragen OneHP, a high-potency development and manufacturing platform at its Nacharam campus in Hyderabad. The new facility strengthens the company’s capabilities in handling and manufacturing highly potent molecules, including cytotoxic payloads used in oncology.

With an integrated service model spanning early discovery through process development and multi-kilogram current Good Manufacturing Practice (cGMP) production, OneHP aims to help pharmaceutical customers advance complex drug development programmes and access clinical and commercial manufacturing capabilities.

Integrated High-Potency Manufacturing Capabilities

Spread across approximately 15,000 sq ft, Aragen OneHP operates one manufacturing line with a designed annual active pharmaceutical ingredient (API) capacity of 500–600 kg. The platform supports highly potent compounds, including cytotoxic molecules and targeted oncology therapies. Furthermore, OneHP provides an integrated manufacturing pathway covering multiple stages of drug development:

Small-scale chemistry synthesis: Up to 10 g

Non-GMP process development and scale-up: Up to 500 g

cGMP manufacturing: 500 g to 5 kg per batch

The facility incorporates advanced containment systems designed to handle compounds at occupational exposure limits of up to 10 ng/m³, subject to ongoing validation. These capabilities support the safe handling of highly potent active pharmaceutical ingredients throughout development and manufacturing.

Supporting Oncology Drug Development and Future Expansion

Highly potent molecules, particularly cytotoxic compounds, require specialised infrastructure, stringent containment measures and controlled manufacturing processes. By bringing synthesis, process development, scale-up and cGMP manufacturing together, OneHP aims to reduce the need for multiple service providers and streamline the transition from early-stage development to clinical and commercial supply. In addition, the platform establishes a foundation for Aragen’s future expansion into advanced drug modalities, including antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs).

Aragen Expands Manufacturing and Development Investments

Aragen OneHP forms part of the company’s broader capacity expansion programme. Aragen invested more than ₹1,000 crore in capital expenditure over the three years ending March 2026, strengthening its capabilities across small molecules and biologics.

During this period, the company’s contract development and manufacturing business recorded a compound annual growth rate (CAGR) of 19%, while its contract research business grew at a CAGR of 12%. As of March 31, 2026, Aragen had installed small-molecule manufacturing capacity of 364 kilolitres across its Hyderabad and Visakhapatnam facilities.

Global Customer Base and Regulatory Credentials

Aragen serves pharmaceutical and biotechnology customers worldwide. In the financial year ending March 2026, nearly 95% of its revenue came from global customers. The company served 591 customers during the year, including 16 of the world’s top 20 pharmaceutical companies. Additionally, Aragen’s Hyderabad manufacturing and analytical operations hold accreditations from several international and national regulatory agencies, including the US Food and Drug Administration (USFDA), European Directorate for the Quality of Medicines & HealthCare (EDQM), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), South Korea’s Ministry of Food and Drug Safety (MFDS), Brazil’s health regulatory agency ANVISA, the World Health Organization (WHO) in Geneva and India’s Central Drugs Standard Control Organisation (CDSCO).

Aragen Highlights the Benefits of an Integrated Platform

Aniel Khubchandani, Chief Executive Officer – Small Molecules-CDMO at Aragen Life Sciences, said, “With OneHP, we are bringing discovery, development and cGMP manufacturing for highly potent molecules onto a more integrated platform. This can reduce handoffs between providers, while keeping process knowledge and programme context connected as a molecule moves from early development towards commercial supply.” As per the press release, with the launch of OneHP, Aragen Life Sciences is strengthening its high-potency manufacturing infrastructure in Hyderabad and expanding its ability to support pharmaceutical customers across the drug development lifecycle.

LyondellBasell appointed Dharmesh Shah as Managing Director – APS, AfMEI. With more than twenty-four years of experience across specialty materials, chemicals and customer-focused businesses, Shah brings extensive industry knowledge and leadership expertise to his new role.

Extensive Experience in Business Leadership

Throughout his career, Shah has demonstrated expertise in identifying and developing growth opportunities, driving strategic transformation and leading high-performing, cross-functional teams. His experience across diverse business environments has equipped him to manage complex business operations and support organisational growth.

Diverse Industry and Technical Expertise

Before joining LyondellBasell, Shah held leadership positions at Philips, Dow Corning, Multibase, MolyKote and Dow Chemicals. During his career, he developed expertise across a broad range of materials and applications, including adhesives and sealants, coatings, potting compounds, thermal and optical materials, specialty lubricants, thermoplastics, silicone rubber and semiconductor applications.

Regional Experience Across South Asia and the Middle East

In addition to his technical and commercial expertise, Shah brings extensive geographic experience across South Asia and the Middle East. His professional background spans technical operations, marketing, customer service and manufacturing, enabling him to connect customer requirements with business and operational priorities. As reported by cxotechbot.com, Shah’s appointment adds an experienced industry leader to LyondellBasell’s management team, bringing a combination of technical knowledge, regional market understanding and strategic business leadership.

CARE Ratings reaffirmed Vinati Organics Limited’s (VOL) long-term credit rating at ‘CARE AA+’ with a Stable outlook. The credit rating agency has also reaffirmed the company’s short-term rating at ‘CARE A1+’, reflecting its strong financial position, established market leadership and healthy debt-servicing capabilities.

Market Leadership and Competitive Advantages

CARE Ratings draws significant comfort from Vinati Organics’ market leadership in two key products: 2-acrylamido-2-methylpropane sulfonic acid (ATBS) and isobutyl benzene (IBB). The company holds a leading position in the global markets for these specialty chemicals. Furthermore, the agency expects Vinati Organics to sustain its competitive advantage in both product segments over the medium term. Its specialised manufacturing processes are difficult to replicate, creating significant entry barriers for potential competitors. The company also benefits from its promoters’ extensive experience and long track record in the specialty organic chemicals industry. In addition, established relationships with reputed customers across geographies support business stability and market reach. Vinati Organics’ backward-integrated manufacturing processes, zero-discharge operations and cost-efficient production further strengthen its competitive position.

Strong Financial Position and Liquidity

The ratings also reflect the company’s healthy cash flows from operations, favourable capital structure, strong liquidity and sound debt-coverage indicators. These factors support its financial flexibility and ability to meet its debt obligations. However, CARE Ratings has highlighted certain risks that could constrain the company’s credit profile. Its total operating income (TOI) remains concentrated in a limited number of key products. Moreover, fluctuations in raw material prices and foreign exchange rates could affect its operating margins.

Factors That Could Improve the Credit Rating

CARE Ratings indicated that significant growth in total operating income, driven by stronger demand for existing products and effective product diversification, could support a positive rating action. Maintaining an operating margin of around 27–30% alongside such growth would further strengthen the company’s credit profile.

Factors That Could Lead to a Negative Rating Action

Conversely, substantial debt-funded organic or inorganic expansion could weaken Vinati Organics’ capital structure and put pressure on its credit ratings. As reported by business-standard.com, additionally, a decline in return on capital employed (ROCE) below 15%, accompanied by an adverse impact on debt-coverage indicators, could trigger a negative rating action.

Brenntag, a global market player in chemicals and ingredients distribution, expanded its distribution agreement with Givaudan, a global leader in fragrance and beauty, taste and wellbeing, to include Australia and New Zealand. Through this expanded partnership, Brenntag will provide customers in the beauty and personal care industry with access to Givaudan Active Beauty’s portfolio of proven cosmetic actives and high-end specialty ingredients. The agreement strengthens the companies’ collaboration across the Asia-Pacific region, combining Givaudan Active Beauty’s ingredient technologies with Brenntag’s distribution network, technical capabilities and local market expertise.

Building on Successful Collaboration in Southeast Asia

The expansion builds on the successful partnership between Brenntag and Givaudan Active Beauty in Southeast Asian markets, including Thailand, Malaysia, Singapore and Vietnam. By extending their collaboration to Australia and New Zealand, both companies aim to improve access to innovative beauty and personal care ingredients while supporting manufacturers and brands across the region.

Advanced Ingredients and Formulation Support

Under the expanded agreement, customers in Australia and New Zealand will gain access to Givaudan Active Beauty’s innovative portfolio of cosmetic actives and specialty ingredients. In addition, Brenntag will contribute its local market knowledge and technical expertise to help customers develop products that meet evolving consumer demands. Through Brenntag’s Innovation & Application Centers, manufacturers will also receive advanced formulation support and tailored solutions. These capabilities aim to streamline product development, accelerate innovation and help customers bring high-performance beauty and personal care products to market faster.

Brenntag Highlights Regional Growth Opportunities

Wissanee Ruangsorn, Regional President, Beauty & Care, Asia Pacific at Brenntag, said the expansion marks an important milestone in the company’s efforts to accelerate beauty and personal care innovation across the region. “The expansion of our collaboration with Givaudan Active Beauty into Australia and New Zealand marks an important milestone in our ambition to accelerate beauty and personal care innovation across Asia Pacific. By combining Givaudan Active Beauty’s technologies with Brenntag’s regional network, technical expertise, and local market insights, we are creating a strong platform to deliver differentiated, high-performance solutions that meet evolving customer needs. “More than an expansion of our geographic footprint, this collaboration connects global innovation with local market opportunities. By sharing expertise and market insights across countries, we can unlock new opportunities, accelerate innovation, and drive sustainable growth for both businesses,” Ruangsorn added.

Givaudan Active Beauty Strengthens Its Presence in Oceania

Bonwook Koo, Regional Head of Sales for Northeast Asia, Southeast Asia and Oceania at Givaudan Active Beauty, highlighted the importance of Australia and New Zealand as markets for beauty and personal care innovation. “Australia and New Zealand are important markets for beauty and personal care innovation, and we are pleased to extend our collaboration with Brenntag to this region. Together, we are expanding access to our active and specialties ingredient offering and supporting manufacturers and brands in creating advanced beauty solutions,” Koo said. As per the press release, through this expanded distribution partnership, Brenntag and Givaudan Active Beauty aim to strengthen ingredient accessibility, support product innovation and create new growth opportunities for beauty and personal care manufacturers across Australia, New Zealand and the wider Asia-Pacific region.

Oil and Natural Gas Corporation Limited (ONGC) has incorporated a new joint venture company, ONGC Petrochemicals Marketing Limited (OPML). The development follows ONGC’s earlier intimation dated April 25, 2026, regarding the formation of the joint venture with Mangalore Refinery and Petrochemicals Limited (MRPL) and ONGC Petro additions Limited (OPaL). Through OPML, the three companies aim to establish an integrated platform to market and trade petrochemicals, chemicals and related products across the ONGC Group.

Integrated Marketing and Trading Operations

OPML will oversee the integrated marketing and trading of the ONGC Group’s petrochemical products. Its responsibilities will cover branding, business development, pricing, distribution, logistics, customer management, sourcing and trading, as well as sales and operations planning. By bringing these functions together, the joint venture aims to streamline marketing activities, strengthen customer engagement and coordinate the commercial operations of the Group’s petrochemical businesses.

Strengthening the ONGC Group’s Petrochemicals Business

The incorporation of OPML aligns with ONGC’s existing downstream and petrochemicals operations. Moreover, the new company will provide a single, market-facing platform for the Group’s petrochemical products, supporting a more coordinated approach to marketing, distribution and trading. As reported by psuconnect.in, the initiative represents a strategic step towards integrating the ONGC Group’s petrochemicals marketing activities and strengthening its presence in the chemicals and petrochemicals market.

A total of 3,898 Indian researchers from 1,185 academic and research institutions have been featured in the 2026 edition of the World’s Top 2% Scientists list, released by Stanford University in collaboration with global academic publisher Elsevier. The recognition highlights the contributions of Indian scientists across a wide range of research disciplines. The Indian Institute of Science (IISc), Bengaluru, led the national tally with 139 researchers, followed by the Indian Institute of Technology (IIT) Delhi with 114. However, India’s representation declined significantly from 6,239 researchers in the 2025 edition to 3,898 in 2026.

Stanford–Elsevier Ranking Evaluates Global Research Impact

The World’s Top 2% Scientists list evaluates researchers worldwide using citation data from the Scopus database, indexed up to 1 August 2026. The assessment relies on a composite citation indicator known as the c-score to measure researchers’ scientific impact. The methodology considers several factors, including total citations, the h-index, co-authorship adjustments and authorship positions. It also calculates indicators both with and without self-citations to provide a broader assessment of research influence. Furthermore, the ranking covers 22 broad scientific disciplines and 174 sub-fields under the Science-Metrix classification system. It publishes two datasets: one assessing career-long research impact and another measuring research performance during a single year. Together, these datasets offer an international benchmark for evaluating scientific contributions and research influence across disciplines and institutions.

IISc and IIT Delhi Lead India’s Representation

The Indian Institute of Science, Bengaluru, secured the highest number of entries among Indian institutions, with 139 researchers on the list. IIT Delhi followed with 114 researchers. Their strong representation highlights the contribution of leading Indian research institutions to scientific advancement across multiple disciplines. Meanwhile, several National Institutes of Technology and private universities also secured recognition, demonstrating the broader reach of India’s research ecosystem.

NIT Rourkela Records 30 Researchers in the Global List

The National Institute of Technology (NIT) Rourkela reported that 29 faculty members and one research graduate featured in the 2026 ranking. The recognised researchers represent diverse fields, including metallurgical and materials engineering, biotechnology, food process engineering, life sciences and mining. Among them, 19 researchers earned recognition in the career-long research impact category. The institute’s representation highlights its contributions to research across engineering, technology and the life sciences. The list also includes Srimanta Patra, a research graduate of NIT Rourkela who currently serves as a Department of Science and Technology (DST)-INSPIRE Faculty member at IIT Guwahati.

KIIT University Reports 34 Researchers

The Kalinga Institute of Industrial Technology (KIIT), based in Bhubaneswar, reported 34 researchers on the global list. Of these, 33 are affiliated with KIIT, while one represents the Kalinga Institute of Social Sciences (KISS). Additionally, 13 researchers secured recognition in the career-long research impact category, reflecting their sustained contributions to scientific research. The results underline the growing participation of private academic institutions in internationally recognised research and publication networks.

Shoolini University Gains Recognition Across 12 Disciplines

Shoolini University in Himachal Pradesh recorded 25 researchers in the 2026 World’s Top 2% Scientists list, with representation spanning 12 scientific disciplines. These fields include biotechnology, pharmacology and environmental sciences, among others. Furthermore, seven faculty members earned recognition in the career-long research impact category. The university’s performance highlights the breadth of research activity across its academic departments and its contribution to India’s presence in global scientific rankings.

Indian Research Institutions Strengthen Global Scientific Presence

The 2026 Stanford–Elsevier list recognises researchers from a broad range of Indian institutions, spanning established research universities, technical institutes and private universities. Although India’s total representation declined compared with the previous edition, the recognised scientists continue to demonstrate the country’s contributions across engineering, medicine, biotechnology, environmental sciences and other research fields. As reported by educationtimes.com, the ranking provides an international reference point for research impact while highlighting the role of academic institutions in advancing scientific knowledge and strengthening India’s global research profile.

India’s pharmaceutical manufacturers are reassessing their global expansion strategies as uncertainty over access to the US market creates new trade risks. At the same time, improved market access through trade agreements is opening opportunities across Europe, the UK, New Zealand and other international markets, according to GlobalData.

The US remains a major destination for Indian pharmaceutical exports, accounting for more than 30% of shipments in 2025, according to India’s Department of Commerce. However, concerns over potential US tariffs on generic medicines are encouraging Indian drugmakers to diversify their export destinations and strengthen their global presence.

US Tariff Risks Prompt Indian Pharma Companies to Reassess Export Strategies

US President Donald Trump’s announcement in July 2026 of significant tariffs on generic medicines has raised concerns about future trade conditions. The measures are scheduled to take effect in 2028, giving Indian pharmaceutical manufacturers time to assess their exposure and explore alternative markets. Although the US remains strategically important, establishing large-scale manufacturing facilities there could increase costs for Indian companies because of higher labour and production expenses. Consequently, manufacturers are evaluating ways to maintain their competitiveness while reducing dependence on a single export market.

Trade Agreements Open New Markets for Indian Pharmaceutical Exports

India’s expanding network of trade agreements could help pharmaceutical companies diversify their export markets and capture additional demand, GlobalData noted in its latest Emerging Market Outsourcing Report. The UK-India Comprehensive Economic and Trade Agreement, which the report states came into force in July 2026, provides Indian pharmaceutical products with duty-free or reduced-tariff access to the UK market. Similarly, India’s trade agreement with New Zealand will remove duties on pharmaceuticals. Meanwhile, the EU-India Free Trade Agreement is expected to improve access to European markets once it takes effect. These agreements could strengthen the competitiveness of Indian drugmakers by reducing trade barriers and creating new opportunities to supply international customers.

Edita Hamzic, healthcare analyst at GlobalData, said, “This is less about India pivoting away from the US and more about its pharmaceutical companies giving themselves more options. As trade tariffs come down in markets such as the UK, Europe and New Zealand, Indian manufacturers have an opportunity to capture a greater share of global pharmaceutical demand.”

CRDMO Sector Creates Additional Growth Opportunities

Beyond finished medicines, India’s contract research, development and manufacturing organisation (CRDMO) sector offers another avenue for international expansion. The sector continues to grow as pharmaceutical companies seek external partners for research, product development and manufacturing. Leading Indian CRDMO companies reported strong double-digit revenue growth in the June 2026 quarter, signalling continued demand for their services. Moreover, India’s established pharmaceutical manufacturing capabilities, technical expertise and competitive operating costs could help domestic companies secure additional international outsourcing contracts. As global pharmaceutical companies reassess their supply chains, Indian service providers have an opportunity to strengthen their position in the global market.

Competition from China Remains a Key Challenge

Despite these opportunities, India faces strong competition from China, particularly in complex biologics. Chinese manufacturers retain significant production scale in this segment, making it difficult for Indian companies to replace them directly. Hamzic said, “India is unlikely to simply replace China, particularly in complex biologics, where Chinese companies retain considerable scale. However, India’s combination of manufacturing experience and competitive costs could help its companies win a larger share of global pharmaceutical manufacturing and outsourcing. The next challenge will be turning improved market access and growing technical expertise into long-term international contracts.”

Indian Pharma Industry Focuses on Global Market Diversification

India’s pharmaceutical industry now has an opportunity to strengthen its global position by combining established manufacturing expertise with improved access to overseas markets. While US tariff uncertainty presents a challenge, new trade agreements and growing demand for outsourced pharmaceutical services could support further export growth. As reported by manufacturingtodayindia.com, sustained success will depend on how effectively Indian pharmaceutical manufacturers convert improved market access, competitive production capabilities and technical expertise into long-term international partnerships.

Birla Carbon, one of the world’s largest manufacturers of high-quality carbon materials, is strengthening its specialty materials portfolio with advanced conductive carbon solutions for demanding industrial applications. The company is focusing on emerging battery technologies and other high-value applications that require reliable conductivity, improved performance and efficient manufacturing processes.

As electrification accelerates across industries, conductive carbon materials are becoming increasingly important in battery development. To highlight its latest solutions, Birla Carbon will showcase its conductive carbon portfolio at The Battery Show North America 2026, scheduled for October 12–15, 2026, at Huntington Place in Detroit, Michigan, USA. Visitors can meet the company’s team at Booth 3029.

Conductive Carbon Materials Enhance Battery Performance

Conductive carbon additives play a vital role in battery electrodes by creating pathways for electron transport. Consequently, selecting the right conductive material can help manufacturers improve charging speeds, high-rate performance and battery cycle life. In addition, advanced conductive additives can support more efficient electrode manufacturing by improving material dispersion and reducing processing requirements. These benefits are becoming increasingly relevant as battery manufacturers seek to enhance performance while controlling production costs.

Birla Carbon Expands Its Specialty Materials Portfolio

Over the past several years, Birla Carbon has strengthened its specialty materials capabilities by developing a portfolio of conductive carbon blacks and carbon nanotubes (CNTs). At The Battery Show North America 2026, the company will present its Conductex™ i conductive carbon black grades, Nanocyl™ carbon nanotubes and carbon black–CNT blend formulations. These solutions address a broad range of conductive applications and are designed to meet evolving requirements across established and emerging battery technologies. According to the company, its portfolio offers high purity, strong electrical conductivity and uniform dispersibility. Furthermore, Conductex™ i conductive carbon black grades can help reduce solvent consumption and energy requirements during battery electrode manufacturing, potentially lowering production costs for customers.

Supporting Next-Generation Battery Technologies

As battery technologies evolve, manufacturers are exploring new chemistries and electrode designs to improve performance, efficiency and commercial viability. Birla Carbon’s conductive carbon solutions are designed to support these developments. The company’s portfolio addresses requirements across established lithium-ion batteries and emerging technologies, including lithium manganese iron phosphate (LMFP), sodium-ion, solid-state and metal-air batteries. By incorporating Conductex™ i carbon blacks and Nanocyl™ carbon nanotubes into battery formulations, manufacturers can tailor conductive networks to meet specific performance and processing requirements.

Industry Collaboration Drives Materials Innovation

Shashank Awasthi, President, Specialty Materials, Birla Carbon, said, “Electrification is creating new performance demands across the materials value chain, and advanced carbon materials have an important role to play in meeting them. At Birla Carbon, we are combining our expertise in carbon materials with an expanding specialty portfolio to help customers address these evolving requirements.” He further highlighted the changing needs of battery manufacturers, particularly their focus on supply chain resilience, extended cycle life and increasingly demanding fast-charging requirements. Awasthi also emphasised that Birla Carbon’s global footprint, technical capabilities and collaborative approach enable the company to work closely with customers to develop solutions tailored to their performance and processing needs.

Conductive Carbon Solutions for Evolving Industry Requirements

Birla Carbon offers conductive carbon additives designed to address key industry priorities, including charge acceptance, battery capacity, dry electrode coating and solid-state battery development. As demand for advanced energy storage solutions continues to grow, the company is focusing on helping manufacturers achieve their performance objectives without compromising product quality, consistency or supply reliability. As per the press release, through its expanding specialty materials portfolio and customer-focused innovation, Birla Carbon aims to support the development of next-generation batteries and other high-performance conductive applications.

Kanoria Chemicals & Industries Ltd. (KCI) commissioned a 12 metric tons per day (TPD) Triacetin manufacturing facility at its existing manufacturing site in GIDC, Ankleshwar, Gujarat. The company launched the facility on 7 October 2026 to strengthen its specialty chemicals portfolio and serve customers in domestic and international markets. The facility marks another step in KCI’s efforts to expand its manufacturing capabilities and meet the growing demand for specialty chemicals across diverse industries.

Triacetin Plant to Serve Domestic and Global Markets

Located at KCI’s existing manufacturing site in Ankleshwar, the facility will produce Triacetin for both Indian and international markets. The company has confirmed that the product is available in India and that it is open to international sales. With a production capacity of 12 TPD, the facility is expected to help KCI address customer requirements more effectively while strengthening its presence in the specialty chemicals segment.

Triacetin Supports Multiple Industrial Applications

Triacetin is a versatile chemical compound used across several industries, including food and beverages, pharmaceuticals, agrochemicals, resins, coatings, plastics and adhesives. Consequently, the addition of Triacetin to KCI’s manufacturing capabilities broadens its ability to serve customers across multiple application areas. The new facility also positions the company to respond to demand from a diverse range of industrial sectors.

KCI Strengthens Its Specialty Chemicals Portfolio

The commissioning of the Triacetin plant reinforces Kanoria Chemicals’ focus on expanding its specialty chemicals business. By adding dedicated production capacity at its Ankleshwar site, the company aims to support customers in India and overseas while strengthening its manufacturing capabilities. As reported by stockssena.com, the facility will support KCI’s efforts to address evolving market requirements and expand its reach in the specialty chemicals industry.

Epsilon Carbon Pvt. Ltd., a global producer of carbon black and specialty carbon products, released its 6th Sustainability Report for FY 2025–26, titled “Anchored in Carbon. Embedded in Circularity.” The report highlights the company’s progress in emissions reduction, energy efficiency, workplace safety, inclusion and community development. It also outlines Epsilon Carbon’s strategy to build a more responsible, resilient and sustainable carbon value chain.

Epsilon Carbon Advances Emissions Reduction and Energy Efficiency

During FY 2025–26, Epsilon Carbon achieved a 98% reduction in Scope 2 emissions intensity compared with its FY 2022–23 baseline. In addition, the company reduced its energy consumption intensity by 6% through operational improvements and more efficient resource utilisation. These achievements reflect the company’s continued efforts to integrate sustainability into its manufacturing operations while delivering reliable carbon materials to customers across the tyre, rubber, manufacturing and industrial sectors.

Waste Heat Recovery Supports Decarbonisation

Epsilon Carbon’s 17 MW captive power plant, which uses waste hot gases generated during production, continues to play a key role in its decarbonisation strategy. During the year, the company achieved 77% utilisation of waste heat recovery, maintaining progress towards its target. By converting waste heat into useful energy and reducing reliance on coal-based power, Epsilon Carbon avoided more than 89,000 tonnes of CO₂ emissions. Furthermore, the company reduced its Scope 3 emissions intensity by 8.13% compared with FY 2024–25. This progress supports its broader efforts to improve environmental performance across the value chain and promote more sustainable manufacturing practices.

Manufacturing Capacity Supports Diverse Industrial Applications

Epsilon Carbon’s manufacturing capabilities enable it to serve customers across a wide range of industrial applications. Its Vijayanagar plant has an annual carbon black production capacity of 215,000 tonnes, alongside a specialty carbon capacity of 5,00,000 tons per annum. These capabilities support applications in tyres, rubber products and other high-performance industrial sectors. At the same time, the company continues to focus on resource efficiency and responsible production to help customers advance their own sustainability objectives.

Workplace Safety, Inclusion and Community Development

Beyond its environmental initiatives, Epsilon Carbon continues to prioritise employee safety, workplace inclusion and social development. During FY 2025–26, the company recorded zero fatalities, reflecting its focus on maintaining a safe working environment. Women accounted for 10% of the Board and 9.41% of the overall workforce during the reporting period. These figures highlight the company’s ongoing efforts to strengthen representation and inclusion across the organisation. Meanwhile, Epsilon Carbon’s corporate social responsibility (CSR) programmes positively impacted approximately 140,000 lives. Through these initiatives, the company supported community development and social progress in areas connected to its operations.

Sustainability Integrated into Long-Term Business Strategy

Vikram Handa, Managing Director of Epsilon Carbon, said, “Sustainability is central to how we are building Epsilon Carbon for the future. Our progress in reducing emissions intensity, increasing the use of waste heat recovery and improving energy efficiency shows what is possible when sustainability is built into everyday operations. “Our customers in tyres, rubber and other manufacturing sectors are also working towards more responsible and efficient value chains. We are committed to supporting them through dependable products, strong manufacturing capabilities and continued innovation. Alongside our environmental priorities, we remain focused on safety, inclusion and creating a positive impact in the communities where we operate.”

Epsilon Carbon Reaffirms Commitment to Responsible Growth

Epsilon Carbon’s 6th Sustainability Report provides stakeholders with an overview of the company’s environmental, social and governance (ESG) performance during FY 2025–26. By combining emissions reduction, waste heat recovery, energy efficiency and community development, the company continues to strengthen its approach to responsible manufacturing. As per the press release, Epsilon Carbon remains focused on operational excellence, sustainable growth and innovation as it expands its role in the global carbon materials industry.